跳至主要内容
临床试验/NCT00452842
NCT00452842终止不适用

An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials.

Pfizer1 个研究点 分布在 1 个国家目标入组 26,784 人开始时间: 2007年10月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Pfizer
入组人数
26,784
试验地点
1

研究概览

简要总结

An observational safety follow up trial will be conducted to monitor the occurrence of cardiovascular events and all cause mortality in subjects who participated in selected torcetrapib/atorvastatin Phase 1, 2, and 3 clinical trials. No hypotheses will be tested.

详细描述

Study A5091075, an observational study in subjects who had previously been treated with torcetrapib, was terminated on 20 Dec 2007. The study was terminated following reviews of final safety information from prior torcetrapib studies and the low participation rates observed during the recruitment period for study A5091075 . On the basis of this new information the Sponsor determined that it was unlikely that this study would result in new and scientifically valid information.

研究设计

研究类型
Observational

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have signed informed consent prior to the initiation of any study-specific activities.
  • Have participated in selected torcetrapib/atorvastatin Phase 1, 2, and 3 clinical trials and were treated with randomized study medication.

排除标准

  • There are no exclusion criteria.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验